AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

Recruiting

Phase 1

Phase 2

AB-2100AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

Sponsor:

Arsenal Biosciences, Inc.

Code:

NCT06245915

Conditions

Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Recurrence

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AB-2100

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by Arsenal Biosciences, Inc. on 2025-07-01.